STAT6 (Phospho_Thr645) Antibody
- Known as:
- STAT6 (Phospho_Thr645) Antibody
- Catalog number:
- E011051-1
- Product Quantity:
- 50ug
- Category:
- Antibodies
- Supplier:
- EnoGene
- Gene target:
- STAT6 (Phospho_Thr645) Antibody
Related genes to: STAT6 (Phospho_Thr645) Antibody
- Gene:
- STAT6 NIH gene
- Name:
- signal transducer and activator of transcription 6
- Previous symbol:
- -
- Synonyms:
- D12S1644, IL-4-STAT
- Chromosome:
- 12q13
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-09
- Date modifiied:
- 2019-04-23
Related products to: STAT6 (Phospho_Thr645) Antibody
Related articles to: STAT6 (Phospho_Thr645) Antibody
- Dendritic cells (DCs) are professional antigen-presenting cells that exhibit significant heterogeneity in development and function. This study found that among 17 cytokines screened, only IL-33 could induce DCs to display a Th9-type cytokine profile, including IL-9, IL-4, and IL-13, in vitro. The response of DCs to IL-33 was synergistically enhanced by TGF-β and IL-4, defining a distinct subset termed DC9. Transcriptomic analysis revealed that DC9 possesses a unique gene expression signature, particularly in cytokine/chemokine clusters, compared to conventional DCs. Mechanistically, DC9 polarization depends on the JAK-STAT6-IRF4 signaling pathway. Functionally, DC9 preferentially drives naive CD4 T cell differentiation toward Th9 cells in vitro. In an ovalbumin-induced allergic airway inflammatory mouse model, DC9 cells were detectable in lungs and adoptive transfer of DC9 exacerbated disease severity, and increased pulmonary Th9 cells. Collectively, we identify DC9 as a novel DC subset induced by IL-33/TGF-β/IL-4 through the JAK-STAT6-IRF4 axis, which promotes Th9 differentiation and aggravates allergic airway inflammation. - Source: PubMed
Publication date: 2026/06/04
Chen YifangZhang QianLi NaZhang ZhaoqiLei TongGuo HanLu HezheZhao Yong - Signal transducer and activator of transcription 6 (STAT6) is a key transcription factor in cytokine signaling, serving as the central effector of the IL-4 and IL-13 pathways. STAT6 orchestrates a range of physiological and pathological processes, including immune homeostasis and tumor development, making it an attractive therapeutic target for Th2-driven diseases and certain cancers. While the development of STAT6-directed agents remains at an early stage, the rapid clinical progression of the highly selective degrader KT-621 has revitalized interest in this target. In this review, we systematically summarize recent advances in STAT6 inhibitors and degraders, with a focus on structural features, design strategies, and biological evaluation. We also highlight current challenges and future opportunities, aiming to provide useful guidance for the discovery and optimization of next-generation STAT6-directed therapeutics. - Source: PubMed
Publication date: 2026/06/05
Liu HuaMa FeihaiWang ZexuLi ZhiyuBian JinleiYuan ZeliWu Tizhi - Interleukin (IL)-33 is a pleiotropic cytokine in the immune system and inflammatory responses, which is involved in cerebral ischemia/reperfusion (I/R) injury. Evidence indicates that IL-33 plays an essential role in macrophage polarization activation, yet the potential molecular mechanisms remain elusive. This study explored the role of IL-33 in the activation of microglia/macrophage-mediated autophagy for cerebral I/R injury via in vitro experiments. - Source: PubMed
Publication date: 2026/01/23
Yong FanLili LinKailiang HuangJinying LinJunping XuXiaohui ZhouYongkai Yang - Water-soluble soybean fiber (WSSF) exerts health benefits beyond its fermentability, but its direct effects on epithelial-immune interactions remain unclear. We investigated whether WSSF regulates antimicrobial proteins (AMPs) in the small intestine and the underlying mechanisms. C57BL/6J and tuft cell-deficient Pou2f3-knockout mice were fed control or WSSF-supplemented diets, and gene and protein expression and cecal microbiota were analyzed. WSSF upregulated the epithelial AMPs SPRR2A, RELMβ, and ANG4 in the jejunum and ileum. Pharmacological inhibition of group 2 innate lymphoid cells (ILC2) or TRPM5 attenuated AMP induction and reduced IL-25, IL-13, tuft cell markers, and STAT6 phosphorylation. WSSF also failed to induce AMPs or type 2 immune markers in -knockout mice, indicating a requirement for tuft cells. Finally, WSSF altered cecal microbiota composition in a tuft cell-dependent manner. These findings identify WSSF as a soybean-derived fiber that strengthens epithelial innate defense via a TRPM5-tuft cell-ILC2 axis. - Source: PubMed
Publication date: 2026/06/03
Ahmad ArslanWijatniko Bambang DwiMapure Siueia Cláudia DomingosYanagi ChisatoIshii YoshikiIshikawa ShodaiInoue RyoRini Dina MustikaYanaka NoriyukiSuzuki Takuya - Immunization engages a highly coordinated series of innate and adaptive immune responses across multiple anatomical sites, a complexity that has contributed to the predominantly empirical nature of vaccine development. To address this limitation, we developed and validated a STAT6 reporter mouse that enables dynamic whole-body imaging and ex vivo characterisation of STAT6-mediated anti-inflammatory signalling. We then integrated this model with an established NF-κB reporter system to dissect the immune activation triggered by two LNP-formulated mRNA vaccines differing in RNA chemistry (unmodified versus N-methylpseudouridine-modified). The dual-reporter approach enabled the construction of a spatiotemporal atlas of vaccine-induced signalling, revealing distinct immune dynamics driven by RNA chemistry and identifying the liver as an early hub for both NF-κB and STAT6 activity following systemic administration. Correlation with serological data showed that early STAT6 activation followed by rapid signal resolution was associated with favourable humoral responses. These findings establish NF-κB and STAT6 reporter mice as rapid in vivo screening tools for early evaluation of vaccine immune potential and highlight their ability to inform more mechanistic and rational design of mRNA vaccine platforms, while emphasising the role of the liver both as a primary LNP target and as an immunologically relevant organ. - Source: PubMed
Publication date: 2026/06/02
Brunialti ElectraPanzeri AlessiaRizzi NicolettaVilla AlessandroMeda ClaraSfogliarini ChiaraPersano StefanoArlati FedericoGuevara Lopez Maria LMartelli CristinaCannavale GaetanoRebecchi MonicaDi Vito ClaraVenturini LetiziaOttobrini LuisaMavilio DomenicoFagerholm SusannaMinucci SaverioVegeto ElisabettaCiana Paolo